{"entity":{"id":"idea-tr2-organoid-matrix-atlas","kind":"idea","name":"A public atlas of drug-pair responses across a thousand patient-derived organoids","aka":[],"tldr":"Build a large, openly shared dataset of how tumour organoids respond to drug pairs, so that anyone can look up which combinations might work for which tumour type.","summary":"Existing combination screens use cell lines (NCI ALMANAC, AZ-DREAM). Organoids preserve more of the patient's tumour biology but no large public pairwise dataset exists. A consortium screening 1,000 characterised organoids (with genomics, transcriptomics and, where available, donor outcome) against a matrix of 100 approved and late-stage drugs would be the training set for every in silico combination model.","asOf":"2026-09-08","links":[{"label":"Cancer Models (HCMI)","url":"https://www.cancer.gov/ccg/research/functional-genomics/hcmi"}],"tags":[],"related":["cancer-models","depmap","idea-tr2-synergy-ranking-engine"],"cancers":[],"sections":[],"technologies":["organoids","functional-drug-testing","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-combination-space","b-preclinical-models","b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Models trained on the atlas will predict clinical combination outcomes (randomised phase 2 success) with better calibration than models trained on cell-line matrices alone, measured against the next fifty combination readouts.","rationale":"Data scale drove progress in every predictive field. The Human Cancer Models Initiative built the organoids; nobody has systematically screened them in combination.","test":"Screen the first 200 organoids across 50 drugs in full pairwise matrices, release the data, and run an open prediction challenge scored on held-out organoids and on existing clinical combination results.","maturity":"preclinical-evidence","actor":"philanthropy","cost":"large","horizonYears":4},"route":"/ideas/idea-tr2-organoid-matrix-atlas/","neighbours":{"collection":[{"id":"cancer-models","kind":"collection","name":"Cancer Models (PDCM Finder) & HCMI","route":"/collections/cancer-models/"},{"id":"depmap","kind":"collection","name":"DepMap (Cancer Dependency Map)","route":"/collections/depmap/"}],"idea":[{"id":"idea-tr2-synergy-ranking-engine","kind":"idea","name":"An open engine that ranks every drug pair by predicted synergy before anyone runs a trial","route":"/ideas/idea-tr2-synergy-ranking-engine/"},{"id":"idea-tr2-reference-model-panels","kind":"idea","name":"Shared reference organoid and PDX panels that every lab can test against","route":"/ideas/idea-tr2-reference-model-panels/"}],"technology":[{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/"},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"bottleneck":[{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"},{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/"},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/"}]}}